(NUVA) Noratis - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE000A2E4MK4
NUVA: Residential, Apartments, Retail, Properties, Housing, Estates
Noratis AG, a German real estate company, specializes in the acquisition, development, management, and sale of residential property portfolios. Its primary focus is on multi-family housing, including apartments, residential areas, and housing estates. The company also maintains a smaller portfolio of retail store properties. Established in 2002 and headquartered in Eschborn, Germany, Noratis AG operates within the German real estate market, targeting undervalued properties for redevelopment and value enhancement. The companys strategy emphasizes medium-term property holding periods, with a focus on generating returns through active asset management and market-driven sales strategies.
From a technical perspective, the stock exhibits bearish momentum. The last price of 1.24 is below the SMA 20 (1.40) and SMA 50 (1.53), indicating downward pressure. The SMA 200 at 2.34 further confirms the stocks decline over the past year. The ATR of 0.07 reflects low volatility, suggesting limited near-term price movement.
Fundamentally, Noratis AG faces challenges in profitability, as evidenced by a negative RoE of -47.23. The companys low P/B ratio of 0.29 and P/S ratio of 0.40 suggest undervaluation relative to its book value and revenue. However, the forward P/E of 8.00 indicates market expectations for improved earnings. The companys market cap of 19.14M EUR reflects its smaller size within the real estate sector.
3-Month Forecast: Based on
Additional Sources for NUVA Stock
NUVA Stock Overview
Market Cap in USD | 14m |
Sector | Real Estate |
Industry | Real Estate - Development |
GiC Sub-Industry | Real Estate Operating Companies |
IPO / Inception |
NUVA Stock Ratings
Growth Rating | -93.8 |
Fundamental | 2.73 |
Dividend Rating | 1.0 |
Rel. Strength | -84.1 |
Analysts | - |
Fair Price Momentum | 0.60 EUR |
Fair Price DCF | 36.90 EUR |
NUVA Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | -100.00% |
Payout Consistency | 43.7% |
NUVA Growth Ratios
Growth Correlation 3m | -94% |
Growth Correlation 12m | -90.5% |
Growth Correlation 5y | -87.6% |
CAGR 5y | -44.77% |
CAGR/Max DD 5y | -0.47 |
Sharpe Ratio 12m | -0.05 |
Alpha | -87.21 |
Beta | 0.219 |
Volatility | 205.40% |
Current Volume | 3.1k |
Average Volume 20d | 2.2k |
As of April 12, 2025, the stock is trading at EUR 0.89 with a total of 3,100 shares traded.
Over the past week, the price has changed by +10.62%, over one month by -17.29%, over three months by -53.17% and over the past year by -82.98%.
Neither. Based on ValueRay Fundamental Analyses, Noratis is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 2.73 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NUVA as of April 2025 is 0.60. This means that NUVA is currently overvalued and has a potential downside of -32.58%.
Noratis has no consensus analysts rating.
According to ValueRays Forecast Model, NUVA Noratis will be worth about 0.7 in April 2026. The stock is currently trading at 0.89. This means that the stock has a potential downside of -26.97%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 1.1 | 23.6% |
Analysts Target Price | - | - |
ValueRay Target Price | 0.7 | -27% |